F-1/A: Phaos Tech Files for Offering Amidst Financial Challenges

Phaos Technology Holdings (Cayman) Limited is filing an amended registration statement for an offering of Class A Ordinary Shares and Warrants, reporting a significant revenue decrease and substantial net losses, while addressing going concern uncertainties.

Summary

• Phaos Technology Holdings (Cayman) Limited is filing an amended registration statement (Form F-1/A) for an offering of Class A Ordinary Shares and Warrants.
• The company reported a significant revenue decline from S$1,882,803 in FY2024 to S$167,707 in FY2025, primarily due to reduced orders from major customers.
• Net losses widened significantly, from S$2,359,844 in FY2024 to S$5,137,064 in FY2025.
• There is substantial doubt about the company's ability to continue as a going concern, with a cash balance of S$54,989 as of October 31, 2025, and negative cash flow from operations.
• The company has reduced its workforce from 25 to 10 employees to manage costs, lowering monthly operating expenses to below S$200,000.
• The company is pursuing a capital raising strategy, including potential equity and debt financing, and has received significant support from its major shareholder.
• The filing details a dual-class share structure where Class B shares have 20 votes per share, potentially discouraging change-of-control transactions.
• The company's technology involves microsphere-assisted microscopy to achieve resolution below the optical diffraction limit, down to 137nm.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant revenue decline, substantial net losses, and substantial doubt about the company's ability to continue as a going concern, despite efforts to diversify and manage costs.

Positives

• The company is actively pursuing a strategy to diversify its customer base and reduce reliance on a few large customers.
• Cost management measures, including a workforce reduction, have successfully lowered monthly operating expenses.
• The company's technology offers super-resolution imaging capabilities (down to 137nm) with practical working distances, differentiating it from traditional microscopy.
• Service revenue has increased due to maintenance contracts, with expectations for this segment to grow.
• The company has obtained ISO 9001/14001/45001 certifications, demonstrating a commitment to quality management.
• The company has received several awards in 2023, including the Titan Business Award for Most Innovative Company of the Year.

Negatives

• Revenue decreased by 91.1% year-over-year, from S$1,882,803 in FY2024 to S$167,707 in FY2025.
• Net loss increased by 117.7% year-over-year, from S$2,359,844 in FY2024 to S$5,137,064 in FY2025.
• The company has substantial doubt about its ability to continue as a going concern.
• Customer concentration remains high, with the top five customers accounting for 85% of revenue in FY2025.
• The company's cash and cash equivalents were only S$54,989 as of October 31, 2025.
• Operating expenses increased by 41.2% in the six-month period ended October 31, 2025, largely due to pre-IPO advisory and public company compliance costs.
• The company has a dual-class share structure that may limit shareholder influence and discourage change-of-control transactions.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and negative cash flow.
• High customer concentration poses a significant risk, as the loss of any major customer could materially impact revenue.
• The company's expansion of direct sales efforts may not be successful and could adversely affect its business.
• Geographic concentration of revenue, primarily from Singapore, exposes the company to regional economic and political risks.
• The market price of Class A Ordinary Shares has been and may continue to be highly volatile, potentially leading to substantial investor losses.
• Failure to maintain the listing of Class A Ordinary Shares on NYSE American could limit investors' ability to trade the shares.
• The company may not be able to successfully implement its business strategies and future plans.
• The company is susceptible to fluctuations in the prices and quantity of materials and components used in its microscopy equipment.

Future Outlook

The company aims to increase and stabilize product sales through customer diversification and regional expansion efforts. However, significant capital raising is required to address liquidity needs and the going concern issue. The company expects service revenue to contribute a greater percentage of revenue going forward.

Management Comments

• Management believes that the workforce reduction has not adversely affected the Company's ability to support its existing operations, attract or retain personnel, or continue implementing its direct sales strategy.
• Management believes these results reflect the initial impact of our efforts to broaden our customer base, reduce customer concentration and improve operational efficiency.

Industry Context

StockSavvy.ai notes that the microscopy equipment market is competitive, with established players like Keyence, Nikon, and Olympus. Phaos Technology's differentiation lies in its patented microsphere-assisted technology, enabling super-resolution imaging below the optical diffraction limit, and its integrated AI software solutions.

Comparison to Industry Standards

• Phaos Technology's super-resolution imaging technology, achieving resolution down to 137nm, surpasses the typical optical diffraction limit of approximately 200nm for conventional optical microscopes.
• The company's integrated AI software for defect detection and pattern analysis aligns with industry trends towards automation and data-driven quality control in manufacturing and research.
• The significant revenue decline and net losses contrast with the growth often seen in established players in the microscopy market, highlighting Phaos's early-stage challenges.

Management Changes

Related Party Transactions

• The Company has received significant financial support from its major shareholder, Tonghuai SG Enterprise Pte. Ltd., in the form of loans totaling S$3,755,423 (approximately US$2,886,043) as of October 31, 2025. These loans are interest-free, unsecured, and due on demand.

Stakeholder Impact

• Shareholders may experience dilution due to the offering and potential future financings.
• Investors face significant risk of losing their entire investment due to the company's financial condition and going concern issues.
• The dual-class share structure may limit the influence of Class A shareholders on corporate matters.
• Employees have faced workforce reductions, but management believes operations and strategy implementation are not adversely affected.

Next Steps

• Complete the offering of Class A Ordinary Shares and Warrants.
• Use proceeds for expansion of supply chain, marketing and promotion, and working capital.
• Continue efforts to diversify customer base and expand into Southeast Asian markets.
• Develop new product series, including those for digital pathology and using Optical Coherence Tomography technology.
• Implement AI and cloud computing capabilities for image processing and analysis.
• Seek ISO 13485 certification for PT Neura to qualify for selling medical equipment.

Key Dates

Recommendation

The company exhibits severe financial distress with a significant revenue decline, widening losses, and substantial going concern risks. While the technology has potential, the current financial instability and high customer concentration make it a very high-risk investment. The planned offering may not be sufficient to overcome these challenges, and investors are likely to face significant dilution and potential loss of capital.

Keywords

microscopy solutions, super-resolution imaging, optical microscopy, AI-assisted inspection, biomedical applications, precision measurement, IPO, registration statement